A self-triggered radioligand therapy agent for fluorescence imaging of the treatment response in prostate cancer

Purpose Radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) is emerging as an effective treatment option for metastatic castration-resistant prostate cancer (mCRPC). An imaging-based method to quantify early treatment responses can help to understand and optimize RLT. Methods We developed a self-triggered probe 2 targeting the colocalization of PSMA and caspase-3 for fluorescence imaging of RLT-induced apoptosis. Results The probe binds to PSMA potently with a K-i of 4.12 nM, and its fluorescence can be effectively switched on by caspase-3 with a K-m of 67.62 mu M. Cellular and in vivo studies demonstrated its specificity for imaging radiation-induced caspase-3 upregulation in prostate cancer. To identify the detection limit of our method, we showed that probe 2 could achieve 1.79 times fluorescence enhancement in response to Lu-177-RLT in a medium PSMA-expressing 22Rv1 xenograft model. Conclusion Probe 2 can potently bind to PSMA, and the fluorescence signal can be sensitively switched on by caspase-3 both in vitro and in vivo. This method may provide an effective tool to investigate and optimize PSMA-RLT.

Automated summary

Radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) is a promising treatment option for mCRPC. A self-triggered probe 2 has been developed for fluorescence imaging of RLT-induced apoptosis by targeting the colocalization of PSMA and caspase-3.